Areas of Interest

We seek partnering opportunities that address unmet medical needs or could significantly improve the standard of care in the following therapeutic areas:

  • Pain management
  • Musculoskeletal disorders
  • Critical care medicine
  • Autoimmune diseases
  • Rare diseases

Pain Management

Asahi Kasei Pharma discovered, developed, and markets the synthetic calcitonin derivative Elcitonin™ (elcatonin) for osteoporosis pain. Under license, we are currently conducting clinical studies of AK1830/ARRY-954 for osteoarthritic pain and low back pain, and AKP-23494954/RQ-00466479 for neuropathic pain. Pain management is one of our focus areas; therefore, we are building a strong portfolio through collaboration and in-licensing activities.

Our current interests

We are seeking pain management opportunities from the preclinical stage to the late stage, marketed pharmaceutical products for pain management, and research collaborations to develop treatments for pain management.

We are specifically interested in compounds targeting neuropathic pain, osteoarthritis pain, low back pain, and fibromyalgia.

Musculoskeletal Disorders

Asahi Kasei Pharma discovered, developed, and markets the osteoporosis therapeutic agent Teribone™ (teriparatide acetate), the synthetic calcitonin derivative Elcitonin™ (elcatonin) for osteoporosis pain. Under license, we developed and market the biologic Xiaflex® (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture.

Our current interests

We are seeking opportunities for musculoskeletal disorders, including osteoporosis, osteoarthritis, and bone diseases, from the preclinical stage to the late stage, as well as marketed pharmaceutical products for musculoskeletal disorders.

Critical Care Medicine

Asahi Kasei Pharma discovered, developed, and markets the biologic Recomodulin™ (thrombomodulin alfa) for disseminated intravascular coagulation (DIC). Under license, we are currently conducting a clinical study of isavuconazole for invasive fungal infection including aspergillosis and mucormycosis. We are reinforcing our R&D pipeline in the field of critical/intensive care as a major area of focus.

Our current interests

We are seeking critical care opportunities from the preclinical stage to the late stage, as well as marketed critical care pharmaceutical products, for the initial phases of critical care treatment.

Autoimmune Diseases

Asahi Kasei Pharma discovered, developed, and markets the immunosuppressant Bredinin™ (mizoribine) for rheumatoid arthritis (RA). Under license, we market Kevzara® (sarilumab) for treatment of RA and are developing AK191/SBI-3150 for systemic lupus erythematosus (SLE).

Our current interests

We are seeking opportunities for autoimmune diseases, including RA, juvenile idiopathic arthritis (JIA), SLE, and systemic scleroderma from the preclinical stage to the late stage, as well as marketed pharmaceutical products. We are also interested in pursuing research collaborations to develop treatments for autoimmune diseases.

Rare Diseases

Our current interests

We are seeking opportunities for rare diseases from the preclinical stage to the late stage, as well as marketed pharmaceutical products. We are also interested in pursuing research collaborations to develop treatments for rare diseases, particularly in the areas of autoimmune diseases, neurodegenerative disorders, and muscular diseases.

Page Top